Former CFO of BlackRock Capital Investment Corporation and AIG Capital Partners' Global Emerging Markets Group Corinne Pankovcin, Joins Aditx Therapeutics as Chief Financial Officer
Aditxt Therapeutics has appointed Corinne Pankovcin as Chief Financial Officer, effective July 2, 2020. With 30 years of experience in public company finance, Pankovcin's previous roles include CFO at Business Development Corporation of America and BlackRock Capital Investment Corporation. Her expertise will support Aditxt's growth and strategic objectives. The company focuses on improving immune system health through innovative technologies. Pankovcin holds a Bachelor’s in Accounting and an MBA, and is a Certified Public Accountant.
- Appointment of Corinne Pankovcin as CFO to enhance financial governance.
- Pankovcin's extensive experience in public company finance may support strategic growth.
- None.
Ms. Pankovcin has 30 Years of Public Company Financial Experience with World Class Organizations
LOMA LINDA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Corinne Pankovcin as Chief Financial Officer, effective as of July 2, 2020.
“Corinne Pankovcin is a skilled financial executive with 30 years of public company financial experience. Her reputation for building strong relationships with key stakeholders, combined with her in depth knowledge of the requirements of SEC regulated public companies, will be of great benefit to Aditxt as we continue to grow the company and execute on our strategic plans. We welcome Corinne to the Aditxt team and look forward to her contributions to our growth,” said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt.
Prior to joining Aditxt, Ms. Pankovcin was the Chief Financial Officer and Managing Director of Business Development Corporation of America (“BDCA”), a business development company, from December 2015 to July 2019. At BDCA, Ms. Pankovcin was responsible for strategic planning, financial forecasting, and financial reporting, in addition to being a trusted advisor and resource to BDCA leadership. From January 2011 to August 2015, Ms. Pankovcin was the Chief Financial Officer and Treasurer of BlackRock Capital Investment Corporation, and a Managing Director of Finance at BlackRock Investment Management LLC. Prior to joining BlackRock, Ms. Pankovcin was a senior member of Finance & Accounting of Alternative Investments and served as Chief Financial Officer for the Global Emerging Markets products group at AIG Capital Partners. Ms. Pankovcin began her career with PricewaterhouseCoopers LLP, where she ultimately held the role of Senior Manager of Business Assurance for Consumer Products, Manufacturing, and Middle Market industries from 1991 to 2001.
Ms. Pankovcin earned a Bachelor of Science degree in Accounting from Dowling College and a Master of Business Administration from Hofstra University. She is a Certified Public Accountant.
About Aditx Therapeutics
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, including the Company’s expectations regarding the proposed offering of the Company’s shares of common stock, including as to the consummation of the offering described above and the size of the offering are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, risk factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations Contact:
PCG Advisory:
Jeff Ramson
Chief Executive Officer
IR@aditxt.com
646-762-4518
www.aditxt.com
FAQ
Who is the new CFO of Aditxt (ADTX)?
What is Corinne Pankovcin's experience prior to joining Aditxt (ADTX)?
What technologies does Aditxt (ADTX) focus on?
What educational qualifications does Corinne Pankovcin have?
